Advances and challenges in cancer immunoprevention and immune interception.
Publication Title
J Immunother Cancer
Document Type
Article
Publication Date
3-21-2024
Keywords
Humans; United States; Cancer Vaccines; Immunotherapy; Neoplasms; Mutation; Tumor Microenvironment; Biomarker; Immune modulatory; T cell; Vaccine.oregon; chiles
Abstract
Invasive cancers typically evade immune surveillance through profound local and systemic immunosuppression, preventing their elimination or control. Targeting immune interventions to prevent or intercept premalignant lesions, before significant immune dysregulation has occurred, may be a more successful strategy. The field of cancer immune interception and prevention is nascent, and the scientific community has been slow to embrace this potentially most rational approach to reducing the global burden of cancer. This may change due to recent promising advances in cancer immunoprevention including the use of vaccines for the prevention of viral cancers, the use of cancer-associated antigen vaccines in the setting of precancers, and the development of cancer-preventative vaccines for high-risk individuals who are healthy but carry cancer-associated heritable genetic mutations. Furthermore, there is increasing recognition of the importance of cancer prevention and interception by national cancer organizations. The National Cancer Institute (NCI) recently released the National Cancer Plan, which includes cancer prevention among the top priorities of the institute. The NCI's Division of Cancer Prevention has been introducing new funding opportunities for scientists with an interest in the field of cancer prevention
Clinical Institute
Cancer
Specialty/Research Institute
Oncology
DOI
10.1136/jitc-2023-007815
